FGFR driver genetic alterations in NSCLC - 102017


FGFR driver genetic alterations in NSCLC

VJOncology has 824 videos Subscribe Here

Description: Shirish Gadgeel, MD of Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI discusses driver genetic alterations, which can be targeted for therapeutic benefit in non-small cell lung cancer (NSCLC). Fibroblast growth factor receptor (FGFR) amplifications and translocations are a common target in several malignancies. Dr Gadgeel discusses a retrospective analysis of patients with FGFR translocations. The data suggests that appropriately targeting and treating FGFR mutations can provide clinical benefit, however, dr Gadgeel points out that FGFR translocations are not common, occurring in 0.4% of patients. Recorded at the 2016 World Congress of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
Shared By : VJOncology
Posted on : 02/14/17
Added : 2 years ago
Category : Other